With the development of precision medicine, molecular targeted therapy has been widely
used in the field of cancer, especially in non-small-cell lung cancer (NSCLC). Epidermal …

The epidermal growth factor receptor (EGFR) is a kind of receptor tyrosine kinase (RTK) that
plays a critical role in the initiation and development of malignant tumors via modulating …

Targeting the epidermal growth factor receptor (EGFR) using tyrosine kinase inhibitors
(TKIs) is highly effective in terms of tumor response rate, survival, and quality of life …

The epidermal growth factor receptor (EGFR) is a well‐characterized oncogene that is
frequently activated by somatic kinase domain mutations in non‐small cell lung cancer …

Since the discovery that non-small cell lung cancer (NSCLC) is driven by epidermal growth
factor receptor (EGFR) mutations, the EGFR tyrosine kinase inhibitors (EGFR-TKIs, eg …

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) have been
established as the standard therapy for EGFR-sensitizing mutant advanced non-small-cell …

Treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)
improves the overall survival of patients with EGFR-mutated non-small-cell lung cancer …

Almost 17% of Western patients affected by non-small cell lung cancer (NSCLC) have an
activating epidermal growth factor receptor (EGFR) gene mutation. Del19 and L858R are the …

The discovery of epidermal growth factor receptor (EGFR) mutations in nonsmall cell lung
cancer (NSCLC) has allowed the identification of a subset of patients whose tumours are …

Identifying activating EGFR mutations is a useful predictive strategy that helps select a
population of advanced non-small-cell lung cancer (NSCLC) patients for treatment with …